Trial Profile

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary) ; Abiraterone; Cabazitaxel; Docetaxel; Enzalutamide; Lutetium-177 PSMA therapy; Sipuleucel-T
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms REASSURE
Sponsors Bayer

Most Recent Events

21 May 2025 According to a Bayer media release, data from this study will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30-June 3.
22 Nov 2024 Status changed from active, no longer recruiting to completed.
24 Apr 2024 Planned End Date changed from 28 Feb 2025 to 24 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com